http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
-
Novocure to Participate in 2026 Leerink Global Healthcare Conference
-
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
-
FDA approves NovoCure's Optune Pax for locally advanced pancreatic cancer
-
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
-
NovoCure reports $655 million 2025 revenue, up 8% from prior year
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
-
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
-
Novocure names Frank Leonard as CEO, replacing Ashley Cordova
-
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
-
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
-
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
-
Novocure Reports Third Quarter 2025 Financial Results
-
Novocure to present TTFields therapy research at european oncology meetings
-
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
-
Novocure to Report Third Quarter 2025 Financial Results
-
Novocure presents positive phase 3 trial results for brain metastases therapy
-
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
-
NovoCure's Optune Lua receives approval in Japan for lung cancer treatment
-
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
-
Novocure Announces Upcoming Investor Events
-
NovoCure gains health coverage in Spain for glioblastoma therapy
-
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
-
NovoCure submits FDA application for pancreatic cancer treatment
-
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
-
Novocure Reports Second Quarter 2025 Financial Results
-
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
-
Novocure to Report Second Quarter 2025 Financial Results
-
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
Novocure Announces Upcoming Investor Events
-
Novocure Reports First Quarter 2025 Financial Results
-
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual
-
Novocure's (NVCR) Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
Novocure to Report First Quarter 2025 Financial Results
-
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
-
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
-
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
-
Novocure (NVCR) Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
-
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields
-
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
-
Novocure (NVCR) Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer Met Primary Endpoint
-
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
-
Novocure to Participate in Upcoming Investor Conferences
-
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
-
Novocure (NVCR): FDA Approves Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
-
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
